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 2011 EMBO Molecular MedicineTherapy of mitochondrial respiratory chain diseases is complicated by limited
understanding of cellular mechanisms that cause the widely variable clinical
findings. Here, we show that focal segmental glomerulopathy-like kidney disease
in Pdss2 mutant animals with primary coenzyme Q (CoQ) deficiency is signifi-
cantly ameliorated by oral treatment with probucol (1%w/w). Preventative
effects in missense mutant mice are similar whether fed probucol from weaning
or for 3 weeks prior to typical nephritis onset. Furthermore, treating symptomatic
animals for 2 weeks with probucol significantly reduces albuminuria. Probucol
has a more pronounced health benefit than high-dose CoQ10 supplementation
and uniquely restores CoQ9 content in mutant kidney. Probucol substantially
mitigates transcriptional alterations across many intermediary metabolic
domains, including peroxisome proliferator-activated receptor (PPAR) pathway
signaling. Probucol’s beneficial effects on the renal and metabolic manifestations
of Pdss2 disease occur despite modest induction of oxidant stress and appear
independent of its hypolipidemic effects. Rather, decreased CoQ9 content and
altered PPAR pathway signaling appear, respectively, to orchestrate the glomer-
ular and global metabolic consequences of primary CoQ deficiency, which are
both preventable and treatable with oral probucol therapy.trics, The Children’s
atrics, The Children’s
of Pediatrics, The
, USA
School of Medicine,
School of Medicine,
rsity of Pennsylvania
sity of California Los
1-267-426-2876;INTRODUCTION
Primary mitochondrial respiratory chain (RC) disease repre-
sents a complex compilation of multi-systemic disorders caused
by pathogenic mutations in more than 60 nuclear and all 37
mitochondrial DNA-encoded genes (Haas et al, 2008). Therapy
for this heterogeneous group of often devastating diseases is
largely relegated to vitamin and supplement cocktails of
theoretical utility whose objective efficacy is difficult to monitor
but which commonly appear to have minimal clinical benefit
(Parikh et al, 2009). A translational mouse model of primary
mitochondrial RC disease caused by a homozygous amino acid
substitution affecting the nuclear-encoded prenyl diphosphate
synthase subunit 2 (Pdss2) enzyme required for coenzyme Q
(CoQ) biosynthesis (Dell et al, 2000; Peng et al, 2004) develops a
lethal kidney disease by 4 months of life (Lyon & Hulse, 1971).EMBO Mol Med 3, 410–427 www.embomolmed.org
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Marni J. Falk et al.CoQ is a highly lipophilic molecule that consists of a
benzoquinone ring joined to a polyisoprenoid side chain that is
comprised predominantly of 9 or 10 isoprenoid groups in mouse
and humans, respectively. The isoprenyl side chain is
synthesized by a heterotetramer of two subunits (Saiki et al,
2005), Pdss1 and Pdss2. In addition to serving an essential role
in electron shuttling within the mitochondrial RC, CoQ has both
antioxidant and oxidant functions (Linnane et al, 2007). Severe,
collapsing glomerulopathy variant, focal segmental glomerulo-
sclerosis (FSGS)-like renal disease in B6.Pdss2kd/kd missense
mutant mice results from CoQ deficiency within glomerular
podocytes (Peng et al, 2008). High-dose CoQ10 supplementation
mitigates renal disease in B6.Pdss2kd/kd mice through approxi-
mately 140 days of life, but does not normalize albuminuria to
control levels, prevent nephritis, nor restore CoQ9 or CoQ10
content in renal tissue (Saiki et al, 2008).
Here, we report the efficacy and results of detailed
mechanistic investigations for both preventative and therapeu-
tic trials in Pdss2 mutant mice with the oral lipophilic drug
probucol.RESULTS
Probucol therapy prevents renal disease in Pdss2kd/kd
missense mutant mice
As probucol was previously reported to be beneficial in a mouse
model of mitochondrial-based glomerular disease caused byTable 1. Effects of probucol or CoQ10 supplementation on renal disease mani
Strain Gender Treatment
group
Treatment
duration
N Age at
sacrifice
(Days)
B6 M No treatment n/a 14 156 48.58
B6 F No treatment n/a 12 156 59.57
B6.Pdss2kd/kd M No treatment n/a 24 135 18.37
B6.Pdss2kd/kd F No treatment n/a 20 136 20.49
B6.Pdss2kd/kd M CoQ10 Birth to sacrifice 7 145 8.29
B6.Pdss2kd/kd F CoQ10 Birth to sacrifice 13 144 16.29
B6.Pdss2kd/kd M CoQ10 Weaning to sacrifice 6 125 4.5
B6.Pdss2kd/kd F CoQ10 Weaning to sacrifice 4 124 3.19
B6.Pdss2kd/kd M CoQ10 Day 100 to sacrifice 6 121 0.94
B6.Pdss2kd/kd F CoQ10 Day 100 to sacrifice 5 121 0
B6.Pdss2kd/kd M Probucol Birth to sacrificea 5 206 0
B6.Pdss2kd/kd F Probucol Birth to sacrifice 3 206 0
B6.Pdss2kd/kd M Probucol Weaning to sacrifice 14 156 30.36
B6.Pdss2kd/kd F Probucol Weaning to sacrifice 11 136 9.43
B6.Pdss2kd/kd M Probucol Day 100 to sacrifice 5 122 0
B6.Pdss2kd/kd F Probucol Day 100 to sacrifice 4 122 0
B6.Pdss2kd/kd M Vitamin E Weaning to sacrifice 9 122 2.85
B6.Pdss2kd/kd F Vitamin E Weaning to sacrifice 10 120 2.20
Probucol therapy significantly prevented renal sequelae that are typically manifest
for only 3 weeks prior to sacrifice, with significant disease prevention still evident t
renal manifestations only when provided fromweaning through 4 months of age, a
treatment durations tested (p< 0.01 at younger age when treated from weanin
p< 0.001 at older age). All values are reported as mean standard deviation. p-Va
to designated (male or female) age-matched untreated B6.Pdss2kd/kd animals.
aProbucol treated missense mutant males showed the greatest therapeutic respo
through the oldest (206 days).
www.embomolmed.org EMBO Mol Med 3, 410–427mutations inMpv17 (Binder et al, 1999), we added 1% probucol
to standard mouse chow (TestDiet) fed to B6.Pdss2kd/kd
missense mutant mice. Probucol effects were compared to
those of long-term CoQ10 supplementation, since high-dose
CoQ10 was previously observed to delay manifestations of renal
disease in young B6.Pdss2kd/kd mice (Saiki et al, 2008). Urine
albumin immediately preceding, and histological nephritis score
immediately following sacrifice were determined in 4–5-month-
old missense mutant littermates placed on standard un-
supplemented diet (controls), probucol supplementation from
birth, weaning or day 100 of life, high-dose CoQ10 supplementa-
tion from birth, weaning or day 100 of life, or vitamin E from
weaning (Table 1). Probucol therapy significantly prevented
renal disease whether administered from the time of weaning
through at least 6 months of age or for only approximately
3 weeks prior to sacrifice. While all of the probucol-treated
missense mutant groups showed significantly higher urine
albumin than gender-matched healthy B6 controls (p< 0.01 in
each case), no significant differences were seen in their mean
nephritis score relative to gender-matched healthy B6 controls
(p> 0.05). Representative examples of normal renal histology
seen in probucol-treated missense mutant animals are illu-
strated in Fig 1. Vitamin E long-term administration from
weaning had modest beneficial effect in female B6.Pdss2kd/kd
mice but no significant effect in males (Table 1). Long-term
CoQ10 therapy also significantly prevented renal disease
manifestations when provided from weaning through 6 months
of age. However, significantly improved renal histology andfestations of B6.Pdss2kd/kd missense mutant mice
Nephritis
score
Urine albumin
(mg/24 h)
Albumin
comparison
group
Albumin
p-value
0.430.46 0.46 0.61
0.630.62 0.22 0.12
1.610.93 10.60 9.12
2.690.99 31.47 30.12 B6.Pdss2kd/kd males p< 0.001
0.690.43 3.64 4.85 B6.Pdss2kd/kd untreated males p< 0.05
0.710.70 2.24 1.79 B6.Pdss2kd/kd untreated females p< 0.001
1.670.75 4.11 2.04 B6.Pdss2kd/kd untreated males p< 0.01
2.260.92 1.75 0.43 B6.Pdss2kd/kd untreated females p< 0.001
1.420.45 10.47 3.47 B6.Pdss2kd/kd untreated males p> 0.05
1.300.40 4.08 1.15 B6.Pdss2kd/kd untreated females p< 0.001
0.60.49 0.76 0.14 B6.Pdss2kd/kd untreated males p< 0.001
1.670.47 19.01 9.50 B6.Pdss2kd/kd untreated females p> 0.05
0.570.82 1.15 1.12 B6.Pdss2kd/kd untreated males p< 0.001
0.550.99 1.42 0.91 B6.Pdss2kd/kd untreated females p< 0.001
1.400.37 0.64 0.17 B6.Pdss2kd/kd untreated males p< 0.001
0.880.55 1.53 0.36 B6.Pdss2kd/kd untreated females p< 0.001
1.560.50 11.58 4.23 B6.Pdss2kd/kd untreated males p> 0.05
1.200.40 11.38 4.72 B6.Pdss2kd/kd untreated females p< 0.01
by 4 months of age whether administered either from the time of weaning or
hrough approximately 6 months of age. CoQ10 therapy significantly prevented
lthough significantly greater effects were seen with probucol than CoQ10 at all
g; p<0.001 at younger age when treated for 3 weeks prior to sacrifice; and
lues were calculated based on urine albumin by Mann–Whitney U-test relative
nse in urine albumin at all ages examined, from the earliest age (122 days)
 2011 EMBO Molecular Medicine 411
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Figure 1. Comparison of probucol-treated and untreated B6.Pdss2kd/kd mouse kidney pathology. Near-normal glomerular histology is evident upon
haematoxylin and eosin staining of renal sections from male probucol-treated missense mutant mice shown at 100X magnification.
A. Wild-type B6 control.
B. Probucol-treated B6.Pdss2kd/kd missense mutant mouse; 128-day old; 0.77mg urine albumin.
C. Untreated B6.Pdss2kd/kd missense mutant mouse; 132-day old; 7.3mg urine albumin. Note tubular dilatation (arrow A), glomerular crescents (arrow B) and
severe interstitial inflammation (arrow C) evident in kidney from untreated missense mutant mouse.
412function was seen when CoQ10 treatment was initiated at birth
rather than upon weaning (Table 1 and Supporting information
File 1). The most dramatic rescue of the renal phenotype
occurred in B6.Pdss kd/kd males that were treated with probucol
from birth to 206 days of age (Table 1). Overall, probucol
provided more long-lasting and effective prevention of renal
disease than did supplemental CoQ10.
Data analysis suggested gender may influence drug treatment
response. A gender effect was seen in response to short-term and
long-term probucol treatments, as male B6.Pdss2kd/kd missense
mutant mice had a significantly greater response in both cases
than did females (p< 0.05). In contrast, short-term CoQ10
therapy for approximately 3 weeks prior to sacrifice had a
significant effect in female B6.Pdss2kd/kd mice but no effect in
males. When directly comparing probucol and CoQ10 treatment
responses, significantly greater improvement following long-
term treatment from weaning with probucol than CoQ10 was
seen among male mice for albuminuria (p¼ 0.001 males and
p¼ 0.1 females) and among both genders for nephritis score
(p¼ 0.03 males and p¼ 0.06 females). Short-term treatment
from day 100 to sacrifice resulted in significantly greater
improvement in both genders treated with probucol relative to
CoQ10 only in albuminuria (p¼ 0.002 males and p¼ 0.008
females) with equivalent effects on the more subjective
nephritis score. Overall, male missense mutant mice tended
to respond similarly or better to probucol therapy, whereas,
females tended to respond similarly or better to CoQ10
supplementation.
Probucol therapy reverses renal disease manifestations in
symptomatic Pdss2kd/kd missense mutant mice
A second cohort of B6.Pdss2kd/kd mice was maintained on
normal chow until approximately 100 days of age and then
tested in metabolic cages for urine albumin. Animals with urine
albumin >1mg in 24 h were placed on probucol-supplemented
chow for approximately 2 weeks, retested in metabolic cages,
and then sacrificed. As shown in Table 2, 24 h urine albumin 2011 EMBO Molecular Medicinein this cohort decreased from 11.46þ/ 12.3mg before to
4.07þ/ 4.22mg after probucol treatment (p< 0.01). A highly
significant reduction occurred in both genders, with a greater
reduction in albuminuria seen in males. Although considerable
variation was present between animals especially prior to
treatment, albuminuria was reduced by probucol treatment in
every instance.
Probucol treatment lowers plasma cholesterol and hepatic
phospholipid levels in B6.Pdss2kd/kd missense mutant and
B6.Podocin/cre,Pdss2loxP/loxP glomerular-conditional knockout
mice
We previously reported that Pdss2 missense mutants develop
hypercholesterolemia that is partly attributable to nephritis and
partly a direct consequence of primary CoQ deficiency, since
blood cholesterol is also significantly increased in B6.Alb/
cre,Pdss2loxP/loxP liver-conditional Pdss2 knockout mice that
have normal renal function (Peng et al, 2008). Probucol has
been previously reported to have potent lipid-lowering proper-
ties, which remain of uncertain mechanism (Stocker, 2009). To
determine whether renal disease resolution on probucol therapy
correlated with its lipoprotein effects, blood cholesterol and
triglyceride levels were determined in both missense and
glomerular podocyte-conditional knockout Pdss2 mutant mice
following long-term probucol treatment (Table 3). We pre-
viously observed that, whereas, B6.Pdss2kd/kd mice with more
advanced stage disease (152þ/ 16 days of age) had sig-
nificantly elevated blood cholesterol,mutantmice up to 133 days
of age did not (Madaio et al, 2005). Similarly, plasma lipids were
not significantly elevated in 4-month-old (mean: 133-day old)
B6.Pdss2kd/kd missense mutant mice that had clear evidence of
renal disease (Table 3). Nonetheless, probucol treatment
significantly decreased plasma cholesterol and triglyceride
levels, as well as renal disease manifestations of albuminuria
and nephritis relative to untreated B6.Pdss2kd/kd missense
mutant littermates (consistent with data presented in Table 1).
Although probucol treatment did normalize the significantlyEMBO Mol Med 3, 410–427 www.embomolmed.org
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Table 2. Renal disease phenotypes following short-term treatment of B6.Pdss2kd/kd missense mutant mice with probucol
Urine albumin (mg/24 h)
Group N Age at first test Probucol treatment duration Pre-treatment test Post-treatment test p-Value
Males 7 1020.49 14.6 1.40 days 14.4019.1 2.321.73 p<0.05
Females 12 1061.37 13.4 2.36 days 10.307.59 5.095.10 p<0.05
ALL 19 1042.52 13.8 2.13 days 11.4612.3 4.074.22 p<0.01
Elevated 24h urine albumin levels suggestive of renal glomerular disease in 100-day-old untreated missense mutants (pre-treatment test) were significantly
reduced in both males and females following approximately 2 weeks of oral probucol treatment (post-treatment test). Histological nephritis score was also lower
following probucol treatment than typical of untreated age-matched missense mutants (Table 1). Non-parametric statistical analysis (Mann–Whitney U-test) of
mean urine albumin in treated versus untreated missense mutant groups showed short-term probucol treatment significantly reduced albuminuria (p¼0.01). A
trend towards greater reduction in urine albumin was seen in males, with a mean reduction by 71.1%þ/ 14.1% in males and 47.1%þ/ 27.6% in females
(p¼ 0.07).
Table 3. Probucol effects on plasma lipids in B6.Pdss2kd/kd missense and B6.Podocin/cre,Pdss2loxP/loxP conditional knockout mice
Mouse strain N Age (days) Treatment Cholesterol (mg/dl) Triglycerides (mg/dl) Urine albumin (mg/24 h) Nephritis score (0–4)
B6 8 160 13 Control 85.96 17.0 75.9424.5 0.50.1 0.070.17
B6.Pdss2kd/kd 16 133 7.2 Control 97.124.8 67.022.3 24.317.2 3.40.5
B6.Pdss2kd/kd 12 169 23.4 Probucol <12.5a 42.719.7 1.61.0 1.01.3
(p< 0.001) (p< 0.01) (p<0.001) (p< 0.01)
Pod/cre 14 150 9.8 Control 369.1168.4 114.551.0 96.631.1 3.70.5
Pod/cre 11 164 3.5 Probucol <63.268.9b 168.377.4 45.633.4 3.40.7
(p< 0.001) (p¼ 0.069) (p<0.01) (p¼ 0.178)
Probucol therapy significantly lowered plasma cholesterol and triglycerides in B6.Pdss2kd/kd missense mutants, as well as plasma cholesterol in renal podocyte-
conditional Pdss2 knockout mutants (‘pod/cre’). While renal disease manifestations of albuminuria and nephritis were prevented by probucol in missense mutants
(consistent with data presented in Table 1), renal disease manifestations were largely unabated by probucol therapy in pod/cre conditional knockouts.
aCholesterol levels in all samples from this group were below the level of detection.
bCholesterol levels in four of the samples from this group were below the level of detection. All values are reported as mean standard deviation. p-Values were
calculated by student’s t-test for each mutation type relative to untreated mutant animals.elevated blood cholesterol that was seen in B6.Podocin/
cre,Pdss2loxP/loxP podocyte-conditional knockout animals, this
lipid-lowering effect was insufficient to prevent or mitigate
severe renal disease in these animals. To determine whether the
hypolipidemic effects of probucol observed in plasma also
extend to the cardiolipin-rich lipid milieu of the inner
mitochondrial membrane in which the RC is located (Schlame
& Ren, 2009), 31P-NMR analysis was performed on combined
liver extracts from two animals per strain and treatment group
(to provide sufficient tissue for analysis). Probucol significantly
reduced liver membrane phospholipids in Pdss2mice, including
cardiolipin, sphingomyelin and phospholipids (Supporting
information File 2). Thus, while probucol is clearly an effective
anti-hyperlipidemic agent, this property was insufficient to
rescue the renal sequelae of severe CoQ deficiency in mice
without Pdss2 activity within renal glomerular podocytes.
Interestingly, prophylactic therapy from birth with Simvastatin,
an anti-hyperlipidemic agent that inhibits HMG-CoA reductase,
neither prevented renal disease nor dramatically lowered blood
cholesterol in Pdss2missense mutant mice (data not shown), as
was similarly observed following Simvastatin administration to
apolipoprotein E-deficient mice (Ivanovski et al, 2008). Overall,
the mechanism by which probucol prevents renal disease in
missense mutant mice with some residual Pdss2 activity within
podocytes (Peng et al, 2008) appears to be independent of its
hypolipidemic effects.www.embomolmed.org EMBO Mol Med 3, 410–427Resistance to oxidative stress is increased in Pdss2 mutant
mice when treated long-term with CoQ10 but not when
treated with probucol
Although CoQ has both antioxidant and oxidant roles (Linnane
& Eastwood, 2004), we observed no evidence of increased
reactive species damage attributable to primary CoQ deficiency
in either Pdss2 missense (kd/kd) or liver-conditional (Alb/cre)
knockout mutants. Specifically, total lipid peroxidation of
isolated liver mitochondria appeared unchanged in either
mutant type relative to wild-type (WT) healthy controls both
at baseline (Supporting information File 3A and B) and
following long-term supplementation with either CoQ10 or
probucol (Supporting information File 3C). To further evaluate
oxidant stress in Pdss2 mice, aconitase activity was assayed in
freeze-thawed liver mitochondria. Whereas, no significant
difference was observed in Pdss2 mutants at baseline or
following long-term CoQ10 therapy relative to B6 controls,
aconitase activity was significantly increased by 15% in
probucol-treated compared to untreated Pdss2 missense
mutants (p< 0.05, Fig 2A).
Antioxidant defenses can be assessed by monitoring induc-
tion of manganese superoxide dismutase (MnSOD), the primary
mitochondrial enzyme to scavenge matrix superoxide (Mac-
millan-Crow & Cruthirds, 2001). MnSOD activity in isolated
kidney mitochondria was significantly increased only in
missense mutant or renal podocyte-conditional (pod/cre) 2011 EMBO Molecular Medicine 413
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Figure 2. Assessment of mitochondrial oxidant stress and scavenging defenses in Pdss2 mutants following supplementation with probucol or CoQ10.
A. Aconitase activity in isolated liver mitochondria is significantly increased in kd/kd mutants treated with probucol relative to untreated littermates (p<0.05
relative to untreated kd/kd mutants). No significant increase in aconitase activity was seen in kd/kd mutants at baseline or upon CoQ10 supplementation.
Results are the average standard error of five measurements per mitochondrial preparation from n¼3–5 female mice. Ages of mice ranged from 140 to
154 days for kd/kd and 215–216 days for B6.
B. MnSOD enzyme activity is significantly increased in kidney mitochondria isolated from missense mutants (kd/kd) and podocyte-conditional knockouts (pod/
cre) treated with CoQ10 relative to respective healthy controls. In contrast, a trend towards decreased mean MnSOD enzyme activity is observed in liver
mitochondria from missense (kd/kd) and liver-conditional knockout (Alb/cre) mutant animals treated with probucol relative to respective healthy controls.
Further, CoQ10-treated missense mutant (kd/kd) animals have significantly greater MnSOD enzyme activity in both liver and kidney relative to probucol-
treated missense (kd/kd) animals. Brackets highlight statistically significant comparisons relative to either untreated controls or between treatment groups, as
indicated. Column height and error bars indicate activity mean and standard deviation (SD), respectively. Dashed red line distinguishes missense mutant (kd/
kd) animals (compared to WT B6 controls) from two different tissue-specific conditional knockout mutants (compared to LoxP controls). kd/kd, missense
mutant; Alb/cre, liver-conditional knockout mutant; pod/cre, renal glomerular podocyte-conditional knockout mutant.
C. SOD2 (mitochondrial MnSOD) hepatic gene expression is significantly increased in kd/kd mutants treated with CoQ10 relative to untreated littermates. In
contrast, SOD2 expression is unchanged relative to B6 WT controls in kd/kdmutants on standard chow with or without probucol supplementation. Values are
reported asmean standard error. Mean age of each groupwas B6, 216 days; kd/kd, 137 days; probucol-treated kd/kd, 144 days; and CoQ10-treated kd/kd 154
days. n¼5 for each group, except CoQ10-treated animals where n¼ 3. All animals were female and the same individuals in which global microarray expression
profiling was performed.
414  2011 EMBO Molecular Medicine EMBO Mol Med 3, 410–427 www.embomolmed.org
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relative to respective healthy controls (Fig 2B). In contrast, a
trend towards decreased MnSOD enzyme activity in isolated
liver mitochondria was seen in missense mutant or liver-
conditional knockout mice treated long-term with probucol.
Significantly greater MnSOD enzyme activity was seen follow-
ing CoQ10 compared to probucol treatment in both liver and
kidney mitochondria from missense mutant mice. Similarly,
hepatic expression of SOD2 (mitochondrial MnSOD) was
significantly increased only in CoQ10-treated missense mutants
(Fig 2C), but unchanged in missense mutants on standard chow
with or without probucol. These data suggest that, while long-
term, high-dose CoQ10 supplementation induces mitochondrial
oxidant scavenging capacity and oxidative stress resistance,
long-term probucol supplementation does not.
Probucol reverses hyperglycemia in B6.Alb/cre,Pdss2loxP/loxP
liver-conditional knockout mice
Given the central role of the liver in intermediary metabolism,
we assessed major blood metabolites indicative of hepatic
function and metabolic control in alb/cre liver-conditional
knockout mice. B6.Alb/cre,Pdss2loxP/loxP mice exhibited no
evidence of liver damage based on histologic (data not shown)
or plasma ALT levels (Supporting information File 4), either at
baseline or following long-term probucol therapy. Blood glucose
was significantly elevated in Alb/cre liver-conditional knockout
mutants (p< 0.05) and significantly decreased by feeding mice
probucol from weaning. No significant difference due to either
Pdss2 knockout in liver or long-term probucol therapy was
observed in blood urea, which is exclusively synthesized in
liver. Although blood ammonia was not increased in Alb/cre
liver-conditional knockout mice relative to B6.Pdss2loxP/loxP
(‘LoxP’) controls, probucol did significantly decrease blood
ammonia relative to both untreated Alb/cre mutants and age-
matched healthy controls (Supporting information File 4). Thus,
probucol appears to have no adverse effect on hepatic function
or biosynthetic capacity and actually appears to have potentially
beneficial systemic metabolic effects by lowering blood levels of
glucose and ammonia.
Probucol therapy reverses global transcriptional alterations
across intermediary metabolic pathways in Pdss2 mice
To discern whether the same transcriptional signature of
mitochondrial dysfunction previously reported in B6.Alb/
cre,Pdss2loxP/loxP liver-conditional knockout mice (Peng et al,
2008) was present regardless of mutation type, as well as to
assess whether pharmacologic therapies modulate expression of
particular pathways, genome-wide transcriptional profiling was
performed in livers from B6.Pdss2kd/kdmissensemutant mice on
standard chow or supplemented long-term with either probucol
or CoQ10. The influence of long-term probucol treatment on
pathway-level expression alterations was also assessed in liver-
conditional Pdss2 knockout mice. Significantly altered KEGG
pathways as determined using Gene Set Enrichment Analysis
(GSEA) to analyse relative genome-wide expression changes in
both mutant types on standard chow and following supple-
mentation with probucol or CoQ10 are visually represented bywww.embomolmed.org EMBO Mol Med 3, 410–427heatmap in Fig 3. Full details of all pathways analysed are
provided in excel format in Supporting information File 5.
Upregulated expression of oxidative phosphorylation
(OXPHOS), the tricarboxylic acid cycle, directly interacting
pathways involved in amino acid metabolism, and cell defense
pathways was previously observed in liver-conditional Pdss2
knockout mice (Peng et al, 2008), as well as in several
mitochondrial RC subunit missense mutant Caenorhabditis
elegans strains (Falk et al, 2008). We now conclude that
upregulation of OXPHOS, protein processing pathways, multiple
immune pathways, and nucleotide metabolism occurs in both
missense and liver-conditional knockout Pdss2 mice. However,
Pdss2 missense mutants uniquely upregulate lipid biosynthesis
and downregulate fatty acid metabolism, amino acid metabo-
lism, glycolysis, cell defenses and peroxisome proliferator-
activated receptor (PPAR) transcriptional signaling pathway
expression. Regardless of the direction of transcriptional
changes in either Pdss2 mutant type, probucol largely (but
not completely, as detailed in Supporting information File 5)
reversed the global pattern of metabolic pathway alterations
(Fig 4). Indeed, long-term probucol therapy in both mutant
types reversed expression alterations within the PPAR signalling
pathway, fatty acid metabolism and glycolysis, despite these
having been concordantly upregulated in knockouts and
downregulated in missense Pdss2 mutants.
Probucol had no significant effect on OXPHOS pathway
upregulation that occurs in these primary mitochondrial RC
mutants, consistent with its apparent inability to serve as an
electron acceptor to replace deficient CoQ in the RC. Further
support for this finding is provided by polarographic RC analysis
of permeabilized skeletal muscle fibres (Oroboros), which
showed no significant difference in RC capacity of probucol
treated B6.Pdss2kd/kd missense mutants relative to untreated
B6.Pdss2kd/kd controls (Supporting information File 6). Further-
more, probucol had no significant effect on gene expression of
major pathways previously linked to its apparent mechanistic
effects in other models, including antioxidant genes (Supporting
information File 7) or heme oxygenase (HMOX1 and HMOX2;
Supporting information File 8).
Branched-chain amino acid catabolism was the most
upregulated KEGG metabolic pathway by either therapy in
Pdss2 missense mutants (Fig 4B and Supporting information
File 5). Steroid biosynthesis and the complement and coagula-
tion cascade were the most downregulated pathways in
missense mutants by CoQ10 and probucol therapy, respectively
(Fig 4A and Supporting information File 5). Steroid biosynthesis
was also the most down-regulated pathway in liver-conditional
knockout mutants on probucol therapy (Supporting information
File 5), a result technically validated on three additional
microarray platforms (Zhang et al, 2010). CoQ10 supplementa-
tion in missense mutants caused a less global and pronounced
‘reversal’ of metabolic alterations than did probucol (Fig 4).
Gene-level heatmap analysis among the most significantly
altered KEGG pathways illustrates that a particular subset of a
given pathway’s genes may drive overall pathway significance
(Supporting information File 9; Zhang et al, 2010). Overall, the
KEGG Atlas overview of intermediary metabolism provides an 2011 EMBO Molecular Medicine 415
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Figure 3. Pathway-level heatmap depicts metabolic pathways whose expression was significantly altered following chronic probucol or CoQ10
supplementation in missense and liver-conditional knockout Pdss2 mutants. Heatmaps clustered by primary metabolic functions are provided for all KEGG-
defined pathways in both mutant types on standard chow alone or with chronic supplementation of either probucol (both mutant types) or CoQ10 (missense
mutants only). This view illustrates that the most significantly altered KEGG-defined pathways fall into several key areas of intermediary metabolism. Probucol
therapy has a dramatic effect in normalizing observed expression alterations across many metabolic domains in both mutant types. Rows represent overall
expression alterations among individual KEGG-defined pathways. Columns represent pair-wise comparisons, from left to right: (1) B6.Pdss2kd/kd versus B6 WT
control; (2) probucol-treated B6.Pdss2kd/kd versus untreated B6.Pdss2kd/kd; (3) CoQ10-treated B6.Pdss2
kd/kd versus untreated B6.Pdss2kd/kd; (4) B6.Alb/CrePdss2loxP/
loxP versus LoxPWT control; and (5) probucol-treated B6.Alb/CrePdss2loxP/loxP versus untreated B6.Alb/CrePdss2loxP/loxP. Red or green colour indicates pathway up- or
down-regulation in the first group relative to the second, where intensity conveys significance of overall pathway alterations for each pair-wise comparison.
Illumina and Affymetrix 30 expression microarrays were used for analysis of B6.Pdss2kd/kd and B6.Alb/CrePdss2loxP/loxP experiments, respectively. Cross-platform
validation of probucol-treated B6.Alb/CrePdss2loxP/loxP versus untreated B6.Alb/CrePdss2loxP/loxP results was performed by replicate analysis of the same samples on
three additional expression microarray platforms, including Illumina (Zhang et al, 2010). Complete GSEA data output including statistical significance for KEGG
pathways analysed in all comparisons are provided in Supporting information File 5.
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Figure 3. Continued
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Figure 4. Probucol has a greater effect than CoQ10 supplementation in normalizing alterations among the most differentially expressed metabolic
pathways in Pdss2 missense mutant mouse liver. The most differentially regulated KEGG-defined pathways as determined in GSEA to have normalized
enrichment score (NES)>1.5 are shown for B6.Pdss2kd/kdmissense mutants relative to B6 healthy controls. Probucol has a more widespread and substantial effect
than does CoQ10 in ‘reversing’, or preventing, expression alterations among pathway that are both upregulated (Panel A) and downregulated (Panel B) in missense
mutants. Bar length represents NES for each pathway as determined in GSEA v2.0. Complete GSEA data output including statistical analyses of all KEGG-defined
pathways analysed in missense animals, as well as in liver-conditional knockout mutants treated with probucol, are provided in Supporting information File 5.
418integrated gestalt of the global metabolic expression
alterations caused by both mutation types and their substantial
normalization with probucol therapy (Supporting information
File 10). 2011 EMBO Molecular MedicinePPAR signaling mediates metabolic consequences of primary
CoQ10 deficiency in Pdss2 mutant mice
The PPAR family of nuclear transcription factors transcription-
ally controls many aspects of metabolism throughmodulation ofEMBO Mol Med 3, 410–427 www.embomolmed.org
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acid homeostasis, as well as inflammation, cell proliferation and
cell division (Feldman et al, 2008). Expression of PPAR pathway
transcription factors and target genes was significantly altered
as judged by global microarray-based transcriptional profiling
analysis in liver from both missense and liver-conditional
knockout mutants, and largely normalized with probucol
therapy (Supporting information File 11). Quantitative Poly-
merase Chain Reaction (after reverse transcription) (RT-PCR)
analysis confirmed that expression of the PPAR-g and PPAR-a
transcription factors were decreased in Pdss2missense mutants
and fully normalized following probucol treatment, but were
unaltered by CoQ10 supplementation (Fig 5A and B). Interest-
ingly, PPAR-g expression was significantly increased in Pdss2
knockout mice but also normalized with probucol therapy
(Fig 5C). PPAR-a expression was unchanged in Pdss2 knockout
mice (Fig 5D). Overall, these data confirm that PPAR expression
alterations occur in primary mitochondrial dysfunction caused
by CoQ deficiency and normalize with probucol therapy.Figure 5. PPAR transcription factor expression normalizes with probucol ther
A. Hepatic expression of PPAR-g and
B. PPAR-a in Pdss2 missense mice is decreased by quantitative RT-PCR validation
exceeding (PPAR-a) expression levels seen in B6 WT controls. CoQ10 supplement
in missense mutants. n¼ 4 female mice per strain and treatment group aged
C. Hepatic expression of PPAR-g is increased by quantitative RT-PCR validation in
decreased by long-term probucol therapy below expression levels seen in WT
D. In contrast, hepatic PPAR-a expression is unchanged in male liver-conditional P
probucol relative to LoxP WT controls. n¼ 3 male mice per strain and treatm
www.embomolmed.org EMBO Mol Med 3, 410–427Probucol therapy increases tissue CoQ content in Pdss2kd/kd
mice
Peroxisomal inducers and PPAR-a signaling agonists are
known to induce CoQ synthesis in mice (Turunen et al,
2004). The enhanced rescue of kidney disease in B6.Pdss2kd/kd
mice achieved by both long- and short-term supplementation
with probucol relative to CoQ10, and the restoration of PPAR-g
and PPAR-a expression in response to probucol treatment,
raised the question of whether probucol alters CoQ tissue
levels. To investigate this possibility, B6.Pdss2kd/kd mice were
fed standard chow alone or supplemented with probucol from
birth to age 207 days, when renal disease severity was assessed
by measuring 24 h urine albumin levels and determining
histological nephritis score (Supporting information File 12).
Liver homogenates were analysed to quantify CoQ9, CoQ9H2,
CoQ10 and CoQ10H2 levels (Fig 6A and B). CoQ9 and CoQ10 in
lipid extracts prepared from the liver of un-supplemented mice
were present exclusively in the oxidized quinone state. In
contrast, lipid extracts from the liver of probucol-supplemen-apy in Pdss2 mutant mice.
, but increased by long-term probucol supplementation either to (PPAR-g) or
ation does not significantly alter expression of either PPAR transcription factor
129–156 days.
liver-conditional Pdss2 knockout mice relative to LoxP WT controls, but clearly
controls.
dss2 knockout mice either on standard chow or supplemented long-term with
ent group aged 120–141 days.
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Figure 6. Probucol supplementation increases content of CoQ9 and CoQ10 in kidney and liver of Pdss2
kd/kd missense mutant mice.
Long-term probucol supplementation
A–D. Pdss2kd/kd mice (3 females and 5 males) were fed diets supplemented with probucol (1%w/w) from birth and killed at 205–207 days of age. Control
B6.Pdss2kd/kd mice (2 females and 2 males) were fed unsupplemented standard chow diet and sacrificed at 205–215 days of age. Each bar represents
the average content of (A) CoQ9 and CoQ9H2 and (B) CoQ10 and CoQ10H2 measured in three aliquots of liver homogenates prepared from each mouse,
calculated as the average of six measurements from three independent sample aliquots. Error bars indicate SD. Twenty-four hour urine albumin levels
collected immediately prior to liver dissection are indicated for each animal. (C) Total CoQ9 content represents the average SD of the sum of CoQ9
plus CoQ9H2 (determined from panel A). (D) Total CoQ10 content represents the average SD of the sum of CoQ10 and CoQ10H2 (determined from panel
B) p< 0.05 and p<0.001.
Short-term probucol supplementation
E–H. Female Pdss2kd/kd mice (100-day old) were fed standard diets plus (n¼ 3) or minus (n¼2) probucol for 15 days. Aliquots of kidney (E and F) and liver
(G and H) homogenates were measured for content of total CoQ9 (E and G) or total CoQ10 (F and H).
p< 0.01. Both CoQ9 and CoQ9H2 and CoQ10 and
CoQ10H2 were present in all extracts, with no differences between them as was observed in extracts prepared from the older mice (205–207 days of age)
following long-term probucol treatment.
420ted animals contained 20–80% of total CoQ content in the
reduced or hydroquinone state (CoQH2). Although no precau-
tions were taken to prevent auto-oxidation of CoQH2, liver
extracts from the un-supplemented and probucol-supplemen-
ted animals were prepared and analysed at the same time.
Thus, the lack of CoQ9H2 and CoQ10H2 is a unique
characteristic of samples prepared from the un-supplemented
B6.Pdss2kd/kd mice. Summation of the hydroquinone and
quinone content for CoQ9 (Fig 6C) and CoQ10 (Fig 6D)
indicated that chronic probucol supplementation significantly
elevated total CoQ content, which correlated with a dramatic
rescue of kidney disease as evidenced by significantly
decreased urine albumin [Fig 6B; average urine albumin in
un-supplemented¼ 50.18 vs. probucol-treated¼ 7.6 (p< 0.01)
and nephritis score (average nephritis score in un-sup-
plemented¼ 3.0 vs. probucol-treated¼ 1.0, p< 0.01)]. Unfor-
tunately, kidneys from these animals were used for histological
purposes and were not available for CoQ content analysis.
Similarly as observed when comparing renal disease severity, a
gender effect was evident when comparing CoQ9 and CoQ10
liver levels (Supporting information File 12). Both CoQ species
were approximately two-fold greater in females than males at
baseline and increased following long-term probucol treatment
in both genders. 2011 EMBO Molecular MedicineGiven the ability of long-term probucol supplementation to
increase tissue CoQ content, the effect of short-term (15 day)
probucol treatment on tissue CoQ content was investigated in
liver and kidney from female B6.Pdss2kd/kd mice already
showing albuminuria (24 h albumin> 1mg) when treatment
was begun. Total CoQ9 content in kidney homogenates was
significantly increased by short-term probucol supplementation
(Fig 6E, p< 0.01). Total CoQ10 content in kidney was also
marginally increased (Fig 6F; p¼ 0.0689). However, no
significant differences in CoQ9 or CoQ10 levels were observed
in liver (Fig 6G and H). Short-term probucol treatment also did
not alter the proportion of hydroquinone in either tissue (data
not shown). Thus, probucol supplementation throughout life
increased hydroquinone and total quinone levels in liver even at
advanced age, whereas, short-term treatment of symptomatic
B6.Pdss2kd/kd mice significantly increased only the kidney total
CoQ9 content.DISCUSSION
Biological significance
This translational investigation of a potential oral therapy for a
genetic-based mitochondrial RC disorder revealed that endo-EMBO Mol Med 3, 410–427 www.embomolmed.org
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more effective than attempts to replace the deficient metabolite
(CoQ) by exogenous CoQ10 supplementation. Probucol treat-
ment successfully improved disease manifestations whether
initiated at birth, at weaning, for a short time (3 weeks) prior to
onset of typical disease manifestations, or even for just 2 weeks
after the onset of the pathophysiologic disease process in
untreated Pdss2 mutant animals. Indeed, the mitochondria
defects that are characteristic of this phenotype can be observed
in most B6.Pdss2kd/kd mice before 100-days old by electron
microscopy (Hallman et al, 2006), and B6.Pdss2kd/kd mice may
manifest significant albuminuria as early as 96-days old (Madaio
et al, 2005). Deficiencies in tissue CoQ content can be observed
even earlier: the average CoQ9 concentration in kidney extracts
from 40-day-old B6 control mice was 1,088 59 pmol/mg
protein, as compared to 292 15 pmol/mg protein in 37-day-
old B6.Pdss2kd/kd missense mutant mice (Saiki et al, 2008).
Therefore, not only does probucol have preventative effects
(Table 1), but it successfully treatsmice after onset of the disease
process, as evidenced by albuminuria (Table 2).
Prophylactic probucol supplementation long-term from birth
to pre-symptomatic animals clearly increased CoQ9 and CoQ10
levels in liver (Fig 6) and prevented nephritis (Table 1). It is
interesting that total CoQ content, particularly CoQ9, was also
modestly but significantly increased in kidney (Fig 6) and all
markers of nephritis (Table 2) were significantly decreased
following only 2 weeks of probucol treatment to B6.Pdss2kd/kd
mice already showing albuminuria (Fig 6). Strong correlation
was similarly observed previously between high-kidney CoQ9
content and low urine albumin in B6.Pdss2kd/kd line Gmice: two
line Gmice that had high-urine albumin also had low renal CoQ9
content, whereas six line G mice that did not manifest evidence
of nephritis all had high-renal CoQ9 content (Saiki et al, 2008).
The gene cluster, ‘ubiquinone biosynthesis’ was not, however,
differentially expressed in liver following long-term probucol
therapy (Fig 3). In particular, expression of ADCK3, the
homologue of yeast COQ8 that appears to regulate Q content
(Barros et al, 2005; Zampol et al, 2010), was not significantly
different by microarray profiling in liver from B6.Pdss2kd/kd
mutants either at baseline or following probucol treatment. It
remains possible that CoQ content could be affected by the rate
of turnover, or it may be that the ADCK3 polypeptide is
regulated by either translational control or post-translational
modifications. Further, while hepatic expression offers the
benefit of assaying a homogenous tissue, it may not be reflective
of CoQ pathway expression changes in renal podocytes.
Although the mechanism by which short-term probucol
treatment increases renal CoQ9 content in symptomatic
B6.Pdss2kd/kd mice remains uncertain, it seems likely that this
effect is important for kidney disease rescue. The increases
detected in de novo content of CoQ (whether due to increased
synthesis or stability) arising from probucol supplementation
are more efficacious than can be attained with CoQ10
supplementation (Saiki et al, 2008). To this end, we have
previously shown that although long-term CoQ10 treatment
partially mitigates albuminuria and nephritis, it does not correct
the CoQ9 or CoQ10 deficiency in B6.Pdss2
kd/kd mouse kidneywww.embomolmed.org EMBO Mol Med 3, 410–427(Saiki et al, 2008). Similarly, defects in the de novo synthesis of
lipoic acid in yeast cannot be corrected by simply providing
lipoic acid exogenously (Hiltunen et al, 2010).
Beneficial effects of probucol administered before the onset
of overt disease manifestations suggests that an effective
application of this lipophilic agent may be as a prophylactic
agent to prevent systemic sequelae of mitochondrial disease. In
addition, significantly reduced albuminuria following onset of
overt disease manifestations suggests that probucol therapy
may also have value as a treatment modality for mitochondrial
disease. Future studies of probucol are needed to discern
whether similar benefit occurs in human subjects, whether its
efficacy is multi-systemic or limited to the kidney, whether
therapeutic effects are detectable if administered to individuals
already manifesting severe disease sequelae, and whether it has
a tolerable safety profile in human patients afflicted with the
heterogeneous class of mitochondrial diseases. No evidence of
overt liver disease (Supporting information File 4) was observed
following long-term probucol administration to Pdss2 mutant
mice, although a significant reduction was seen in blood
cholesterol, glucose, and ammonia as well as in hepatic
phospholipid content (Supporting information File 2). Patients
with a multi-systemic infantile form of CoQ10 deficiency who
harbour mutations in PDSS1, PDSS2, COQ2 or COQ9 may also
exhibit renal disease, which in some cases has been reported to
respond to treatment with CoQ10 (Quinzii & Hirano, 2010). It
will be important to evaluate the efficacy of probucol therapy in
these patients.
Investigation of additional possible mechanisms underlying
probucol efficacy in Pdss2 mutants
Probucol is structurally comprised of two phenol rings joined by
a disulfide bridge. It represents a chemical prototype fromwhich
newer generation analogues have since been generated that lack
some potentially deleterious effects of probucol (Stocker, 2009),
including lowering HDL cholesterol and prolonging cardiac
repolarization (QTc interval). While neither of these parameters
was specifically assessed in probucol-treated Pdss2 mice, we
observed no incidence of sudden or unexplained death as might
be seen with prolonged QTc in treated animals up to 8-months
old. The mechanisms by which probucol lowers plasma lipid
levels, acts as an antioxidant, and fights inflammation remain
active areas of investigation (Stocker, 2009). Probucol has
recently been reported to have renal protective effects during the
administration of nephrotoxic agents (Yin et al, 2009), as well as
beneficial effects on cardiac and neurologic function in the face
of oxidative stress (Farina et al, 2009; Wu et al, 2006; Zhou et al,
2009). It has successfully been used to prevent restenosis after
coronary angioplasty (Tardif et al, 1997) and also prevents
atherosclerosis and related cardiovascular diseases associated
with increased oxidative stress and inflammation in several
animal models, where its efficacy has been attributed to
induction of heme oxygenase (Wu et al, 2006). However, heme
oxygenase gene expression was not significantly altered by
probucol treatment in either missense or liver-conditional Pdss2
knockout mice when analysed by expression microarray
profiling of liver (Supporting information File 8). 2011 EMBO Molecular Medicine 421
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422Probucol’s ability to prevent renal disease in this model
highlights the question of what aspect of CoQ function underlies
the etiology of glomerular disease in Pdss2 mutants having
primary CoQ deficiency. It does not appear likely that their renal
disease results solely from decreased electron transport capacity
in kidney (Peng et al, 2008). Although probucol supplementa-
tion clearly increased tissue CoQ content (Fig 6), it did not
appear to improve mitochondrial respiratory capacity (Support-
ing information File 6). Nor does severely diminished RC
capacity necessarily cause renal disease in many forms of
primary mitochondrial disease.
Antioxidant properties attributed to probucol appear related to
its sulfur atoms more so than its phenol rings (Wu et al, 2006).
Resolution of renal disease with probucol, therefore, makes
increased oxidative stress in the setting of primary CoQ deficiency
an attractive candidate to explain the pathophysiologic mechan-
ism of Pdss2-related renal disease. Oxidative stress has also been
linked to other forms of primary renal glomerular disease that
have diverse etiologies including infection, altered immune
responses and altered lipid metabolism (Mayrhofer et al, 2009).
However, we were unable to demonstrate evidence of increased
oxidative stress, oxidative damage or major oxidant scavenging
response in either liver or kidney mitochondria isolated from
Pdss2mutant animals. Rather, aconitase activitywas significantly
increased by 15% only following probucol treatment (Fig 3A). In
addition, long-term treatment with only vitamin E, another
lipophilic antioxidant, did not substantially ameliorate renal
disease in B6.Pdss2kd/kd mutant mice. Finally, no significant
expression alterations were seen in either individual antioxidant
scavenging genes or at the level of concordant antioxidant
pathways in Pdss2 missense or liver-conditional knockout
mutants supplemented long-term with probucol (Supporting
information File 7). Nonetheless, it is well recognized that gene
expression changes are not necessarily indicative of cellular
antioxidant response. It remains possible that the endogenous
boost in tissue CoQ content elicited by probucolmay function as a
crucial antioxidant in podocyte cellular membranes. Analysis of a
fibroblast cell line from the sole human patient reported to be
affected with an autosomal recessive Pdss2-based disease (Lopez
et al, 2006) identified nearly 90% CoQ10 deficiency and impaired
ATP synthetic capability, but similarly as observed in the Pdss2
mutant mice, found no sign of increased oxidant stress as
assessed by relative oxidant species production and antioxidant
defense markers (Quinzii et al, 2008).
Inflammation may play a pathogenic role in Pdss2-related
nephritis, as probucol has been previously shown to reduce
mononuclear cell adhesion to endothelium in vivo as well as to
inhibit macrophage infiltration. Indeed, we have previously
observed substantial inflammatory infiltrates in kidneys of
B6.Pdss2kd/kd mutants and rearing animals in germ-free
conditions substantially mitigates renal disease (Hallman et
al, 2006). We also found many immune pathways to have
significantly upregulated expression in livers of Pdss2 mutant
mice, alterations that were largely reversed with probucol
therapy (Supporting information File 5).
Probucol’s well-described effects on lipid metabolism, which
include reduction of LDL and HDL levels (Stocker, 2009), 2011 EMBO Molecular Medicineprompted us to investigate whether altered lipid metabolism
that occurs in the setting of Pdss2-related CoQ deficiency
correlates with their renal disease. Expression profiling in Pdss2
missense mutant liver demonstrates these animals do have
aberrant lipid metabolism, involving upregulation of lipid
biosynthesis and downregulation of fatty acid oxidation (Fig 3
and Supporting information File 10). Plasma lipid abnormalities
have also been previously observed to develop with age in both
missense and liver-conditional knockout Pdss2mutants (Peng et
al, 2008), and here we report that significant hypercholester-
olemia occurs in podocyte-conditional Pdss2 knockouts
(Table 3). Our data show that both plasma lipids (Table 3)
and membrane phosphoplipids in liver (Supporting information
File 2) are significantly decreased by probucol therapy. Thus, it
is possible that the dramatic prevention of renal disease by
probucol supplementation may relate to its role in reversing the
lipid abnormalities caused by Pdss2 deficiency. Indeed, a
combination of altered lipid metabolism and oxidative stress
was recently shown to underlie puromysin aminonucleoside
nephrosis. Downregulation of enzymes involved in antioxidant
pathways and fatty acid oxidation was detected at the protein
level in cultured podocytes from puromycin aminonucleoside-
treated animals (Mayrhofer et al, 2009), similar to what we
observed at the expression level for fatty acid oxidation in Pdss2
mutant mice. However, we found renal disease and cholesterol
levels were both unaltered when Pdss2 mutants were treated
long-term with a classic anti-hyperlipidemic agent that inhibits
HMG-CoA reductase, Simvastatin. Furthermore, efficient anti-
hyperlipidemic activity of probucol in mice without Pdss2 activity
within renal glomerular podocytes was insufficient to rescue their
severe nephritis. Thus, the mechanism(s) by which probucol
prevents renal disease in missense mutants with reduced or no
Pdss2 activity within podocytes (Peng et al, 2008) are likely not
fully dependent on the drug’s hypolipidemic effects.
Finally, we show here that the redox state of CoQ is altered in
liver of older Pdss2kd/kd mice (Fig 6). Several reports have
indicated that CoQH2/CoQ redox status may decrease in various
disease states (Kontush et al, 1997; Lim et al, 2006; Mabuchi
et al, 2005; Vasta et al, 2011; Wada et al, 2007). Such differences
were not noted in our prior analyses of tissue CoQ levels in 180-
day-old Pdss2kd/kd mice, as we had previously utilized an
oxidizing pre-column electrode to oxidize hydroquinones and
generate just the quinone species (Peng et al, 2008; Saiki et al,
2008). Thus, it will be important to monitor CoQH2/CoQ ratios
as a function of disease progression and response to probucol in
future studies of this model of FSGS-like renal disease.
It is interesting to compare Pdss2 mutants with the other
mouse mutant whose kidney disease is ameliorated by
probucol, the Mpv17 knockout mouse. Both models involve
primary mitochondrial defects and have severe proteinuria
caused by a kidney disease similar to FSGS. Kidney disease
occurred before 6 months of age in Mpv17/ mice that were
initially identified as a result of insertional inactivation (Weiher
et al, 1990). Subsequently, no trace of proteinuria or renal
pathology could be observed through at least 12 months of age
after backcrossing the transgene to C57BL/6 (Spinazzola et al,
2006), although the renal pathology was again observed whenEMBO Mol Med 3, 410–427 www.embomolmed.org
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et al, 2009). Apparently, the original mixed CFW background
enhanced the renal phenotype to a greater extent than did the
inbred C57BL/6 background. The Pdss2kd/kd genotype has so far
been studied only two backgrounds, CBA/CaJ and C57BL/6
(B6), which have appeared equivalent in their effects on the
renal phenotype (unpublished observations). The fact that
kidney disease in both Mpv17/ and Pdss2kd/kd mice can be
ameliorated by probucol is puzzling, but may relate to an
exquisite sensitivity of glomerular podocytes to mitochondrial
dysfunction. Precisely how probucol may remedy the effects of
primary mitochondrial deficiency in renal podocytes remains to
be determined.
Effects of chronic CoQ10 supplementation in primary
CoQ deficiency
Primary CoQ deficiency in humans has been shown to represent
a rare form of mitochondrial RC disease that has four major
clinical presentations, which are often but not universally
ameliorated by CoQ10 supplementation (Quinzii et al, 2007). As
mice and humans differ in their major CoQ isoform (CoQ9 and
CoQ10, respectively), it remains possible that the failure of high-
dose CoQ10 supplementation to prevent or cause sustained
improvement of disease manifestations in Pdss2 mutant mice
may relate to the minor CoQ10 isoform we supplied. It may also
relate to relatively low tissue bioavailability of the formulation
used. While CoQ10 is generally a first-line supplement for all
forms of human RC disease (Parikh et al, 2009), little in vivo
evidence either supports or refutes its use despite concerns that
CoQ10 plays an important role as both an antioxidant and pro-
oxidant (Haas, 2007; Linnane et al, 2007). This study provides
evidence that chronic high-dose CoQ10 supplementation of
Pdss2mutant mice in equivalent doses to that provided to many
human patients does induce antioxidant defenses, as assessed
by both activity and relative expression assays of the prime
mitochondrial antioxidant defense enzyme, MnSOD (Fig 2).
Aconitase activity as a marker of oxidative stress (Fig 2) and
qualitative analysis of 4-HNE-based mitochondrial lipid perox-
idation (Supporting information File 3) were unchanged in both
untreated and CoQ10-treated mutant mice relative to age-
matched controls. Future study will be required to determine
whether increased oxidant scavenging capacity ultimately
represents a pro-oxidant or antioxidant effect.
Metabolic pathway expression profiling as a tool to survey
cellular consequences and treatment response in
mitochondrial disease
Applying metabolic pathway clustering to global transcriptional
profiling presents a powerful opportunity to reduce the
complexity of describing metabolic regulation in mitochondrial
disease. We previously reported that mice harbouring condi-
tional homozygous hepatic deletion of Pdss2 have altered
intermediary metabolism characterized by amino acid abnorm-
alities and upregulated expression of 15 basic intermediary
metabolic and cellular defense pathways (Peng et al, 2008).
Here, we show that while these mice manifest mild but
significant hyperglycemia, they do not have obvious abnorm-www.embomolmed.org EMBO Mol Med 3, 410–427alities of liver transaminase (ALT) or synthetic function (urea;
Supporting information File 4). We further now report that
significantly altered hepatic expression of many metabolic
pathways also occurs in spontaneous Pdss2 missense mutants
(Fig 3). We conclude that while the transcriptional signatures of
these two mutant types are in many ways distinct, several
metabolic pathways are similarly upregulated in both missense
and knockout Pdss2 mutants, including OXPHOS, protein
processing, immune pathways and nucleotide metabolism.
Future study of intermediary metabolic flux alterations by
isotopic profiling in both mutant types will be necessary to
dissect whether the direction, rather than mere occurrence, of
transcriptional alterations in multiple metabolic pathways is
indicative of a specific adaptive response to primary mitochon-
drial dysfunction. Interestingly, the direction of altered expres-
sion for multiple intermediary metabolic pathways directly
correlated in both mutant types with the direction of altered
PPAR pathway signaling, and in particular, with PPAR-g
expression (Figs 3 and 5).
Probucol supplementation largely reversed transcriptional
alterations not only globally across many aspects of inter-
mediary metabolism but also in PPAR pathway signaling (Fig 4
and Supporting information Files 5 and 11). Altered expression
of key PPAR pathway transcription factors expressed in liver
was confirmed by quantitative RT-PCR, showing that PPAR-g
was upregulated in the liver-conditional knockout mice while
both PPAR-a and PPAR-g were downregulated in missense
mutants, all of which normalized on probucol therapy (Fig 5).
While high-dose supplemental CoQ10 therapy normalized
expression of several pathways in Pdss2 missense mutants,
its effect was less pronounced than that of probucol (Fig 4).
Furthermore, CoQ10 supplementation neither normalized PPAR
signalling (Fig 5) nor prevented kidney disease (Table 1). PPAR
pathway activation by oral bezafibrate therapy has also been
demonstrated to improve a myopathy caused by mitochondrial
complex IV dysfunction in a COX10 mutant mouse (Wenz et al,
2008). Our findings suggest that PPAR pathway signaling
alterations may orchestrate the global metabolic consequences
of primary mitochondrial RC dysfunction. It is possible that
probucol enhances PPAR signaling in Pdss2 missense mice,
which then induces CoQ content. Indeed, there is considerable
evidence for PPAR-induction of CoQ biosynthesis in response to
peroxisome proliferators (Turunen et al, 2004). Alternatively,
the increase in CoQ (and CoQH2) levels in response to probucol
may be the switch that elicits PPAR signalling. PPAR induction in
response to CoQ10H2 supplementation has been reported in
SAMP1 mice (Schmelzer et al, 2010).
Metabolic pathway profiling thus appears to offer a sensitive
means to elucidatemechanisms and tomonitor treatment effects
in primary mitochondrial disease. Pathway expression profiling
in individual human mitochondrial disease patients who have
widely different genetic causes for their diseasemay offer a route
to effectively tailor clinical treatment regimens. In particular, it
would be of interest to discern whether the global metabolic and
transcriptional sequelae of RC dysfunction we observed in the
mouse model of Pdss2 deficiency (Peng et al, 2008) are evident
in the sole reported Pdss2 patient cell line, andwhether probucol 2011 EMBO Molecular Medicine 423
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The paper explained
PROBLEM:
Mitochondrial RC defects are inherited diseases for which
effective therapy has remained elusive. Simply providing a
missing metabolite frequently has no clinical efficacy even when
the specific enzymatic defect is well defined. For example, while
some children born with defective CoQ biosynthesis respond to
CoQ10 supplementation, many do not. We study a mouse model
of a fatal renal glomerular disease caused by primary CoQ
deficiency. These Pdss2 mutant mice show only limited
therapeutic response to lifelong CoQ10 supplementation. During
our investigation of other potential therapeutic agents, we have
discovered that probuocol, a lipid-soluble antioxidant drug with
lipid-lowering and anti-inflammatory activities of uncertain
mechanism previously used to treat hyperlipidemia, has
considerably greater therapeutic efficacy for the renal and
metabolic disease sequelae in these mice than CoQ10 supple-
mentation. Understanding the basis for the effectiveness of this
drug could provide a valuable lead towards designing novel
therapies for human mitochondrial diseases.
RESULTS:
We demonstrate that long-term oral administration of probucol
prevented an otherwise lethal glomerulopathy in B6.Pdss2kd/kd
mice through at least 6 months of life. By contrast, long-term
prophylactic CoQ10 supplementation was comparatively less
effective for renal disease prevention, despite its induction of
mitochondrial oxidant scavenging capacity. Short-term admin-
istration of probucol limited to just 2–3weeks before the onset of
nephritis also prevented renal disease, whereas, short-term
supplementation with CoQ10 had no effect in males and only a
modest therapeutic effect in female mutant mice. Remarkably,
probucol treatment also significantly mitigated renal disease
when fed for only 2 weeks to already symptomatic B6.Pdss2kd/kd
animals. Mechanistic investigations demonstrated that despite a
modest induction of oxidative stress, probucol administration
substantially prevented renal disease and largely reversed global
metabolic pathway transcriptional abnormalities. Probucol’s
beneficial effects on the renal and metabolic manifestations of
Pdss2 disease appeared to be independent of its hypolipidemic
properties. However, when administered from birth through
6 months of life, probucol significantly increased both the
hydroquinone (CoQ9H2 and CoQ10H2) and total CoQ9 and CoQ10
content in liver. Furthermore, treating symptomatic animals with
probucol for only 2 weeks beginning at day of life 100
significantly increased CoQ9 levels in mutant kidney. Finally, we
observed that the mitochondrial RC dysfunction caused by
primary CoQ deficiency in Pdss2 mutant mice elicited aberrant
expression of many intermediary metabolic pathways and PPAR
transcription factor pathway signaling, which were all signifi-
cantly rescued by probucol treatment.
IMPACT:
These data suggest that decreased CoQ9 content and altered
PPAR pathway signaling may orchestrate the glomerular and
global metabolic consequences of primary CoQ deficiency,
respectively. Remarkably, these renal and metabolic sequelae of
primary mitochondrial RC dysfunction were both preventable
and treatable with oral probucol therapy. Thus, targeting the de
novo supply of CoQ may be a more effective therapeutic strategy
than supplementing the missing co-factor.
424has any discernible modifying effect. Furthermore, elucidation
of common pathway alterations across different classes of RC
dysfunction may permit the development of pathway-targeted
therapies for the difficult to treat class of primary mitochondrial
disorders (Parikh et al, 2009).
Probucol is a lipophilic agent with previously reported
antioxidant, anti-inflammatory and lipid-lowering properties
(Stocker, 2009) that we found to prevent an otherwise lethal
renal glomerular disease as well as expression alterations across
many domains of intermediary metabolism in a Pdss2 mutant
mouse model of mitochondrial RC disease caused by primary
CoQ deficiency. The beneficial effects of probucol exceeded
those of supplemental CoQ10, both in terms of ameliorating
renal disease and increasing tissue CoQ content. Furthermore,
probucol treatment reversed albuminuria in B6.Pdss2kd/kd
missense mutant animals that already manifested renal disease.
The renal efficacy of probucol appears to lie in its ability to
increase tissue CoQ content, although it is not yet known
whether this phenomenon is mediated through enhanced de
novo synthesis or decreased degradation. Probucol’s beneficial 2011 EMBO Molecular Medicineeffects on the renal and metabolic manifestations of Pdss2
disease occur despite its modest induction of oxidant stress and
appear to be independent of its hypolipidemic effects.
In summary, the data suggest that decreased CoQ9 content
and altered PPAR pathway signaling orchestrate the glomerular
and global metabolic consequences of primary CoQ deficiency,
respectively, which are both preventable and treatable with oral
probucol therapy. Thus, we conclude that it is more important to
induce the de novo supply of CoQ in the Pdss2kd/kd CoQ deficient
animals, than to directly supplement the missing co-factor
(CoQ10).MATERIALS AND METHODS
B6.Pdss2kd/kd missense mutant mice treatment groups
B6.Pdss2kd/kd mice were derived by backcrossing a recombinant
chromosome derived by positional cloning onto the B6 background
(Dell et al, 2000). B6.Pdss2kd/kd mice in this report were in the 13th
backcross generation. Untreated mice were fed a standard LabDietEMBO Mol Med 3, 410–427 www.embomolmed.org
Research Article
Marni J. Falk et al.rodent chow obtained from PMI Nutrition International (Brentwood,
MO). Probucol-treated mice were either given the same diet to which
1%w/w probucol was added (Animal Specialties and Provisions,
Quakertown, PA), which we estimate resulted in a final daily dosage of
approximately 95mg per kg body weight. The gender, ages and
lengths of time that different groups of mice were treated with
probucol are shown in Tables 1 and 2, and Supporting information File
12. For the mice in Table 2, urine albumin was measured at 100 days
of age and only those with significant albuminuria (>1mg in 24h)
were treated with probucol. Mice fed diets supplemented with
probucol from birth (Fig 6) were raised by mothers fed probucol
supplemented diets 1%w/w until weaning, and, thereafter, fed a
probucol supplemented 1%w/w chow diet. CoQ10-treated mice
received a standard chow with CoQ10 (LiQsorb; Tishcon Corp.,
Westbury, NY) added to their drinking water from either birth,
weaning or day of life 100, as specified in Table 1. The amount of
CoQ10 added was 1mg/ml, which we estimate resulted in a final daily
dosage of approximately 400mg CoQ10 per kg body weight. Vitamin E
was provided from weaning in standard chow at a dose of 300 IU
per kg chow (Animal Specialties and Provisions), which we estimate
resulted in a final daily dosage of approximately 29 IU per kg body
weight. Simvastatin treatment consisted of feeding mice chow
with 0.1%w/w Simvastatin from weaning, which we estimate
resulted in a final daily dosage of approximately 100mg per kg body
weight. All studies were carried out in accordance with NIH guidelines
and approved by the Institutional Animal Care and Use Committees
of The University of Pennsylvania and The Children’s Hospital of
Philadelphia.
Tissue-specific conditional Pdss2 knockout mice treatment
groups
Liver-conditional and podocyte-conditional Pdss2 knockout mice were
generated as previously described (Peng et al, 2008). Briefly, for liver-
conditional knockout the mutation was targeted to hepatocytes
utilizing mice homozygous for the floxed gene (B6.Pdss2loxP/loxP)
crossed with partners that expressed cre under the control of an
albumin/cre promoter (B6.Cg-Tg(Alb-cre)21 Mgn/J (Alb/cre)) obtained
from The Jackson Laboratory. Two B6.Alb/cre,Pdss2loxP/loxP mice (one
male and one female) were fed standard mouse chow supplemented
with probucol (1%w/w) from weaning beginning on day of life 44
(Zhang et al, 2010). Untreated controls consisted of two B6.Alb/
cre,Pdss2loxP/lox mice (one male and one female) fed standard mouse
chow. Animals were sacrificed and liver specimens flash frozen for RNA
extraction at 140–169-day old. Podocyte-specific knockouts (B6.Po-
docin/cre,Pdss2loxP/loxP) were obtained by crossing mice homozygous
for the floxed gene with partners that expressed cre under the control
of the Podocin promoter (Moeller et al, 2000). Probucol and CoQ10
supplementation were provided to podocyte-conditional knockouts
from birth in the same fashion as described above for missense
mutants. All procedures were carried out in accordance with NIH
guidelines were approved by the Institutional Animal Care and Use
Committee of both The University of Pennsylvania and The
Children’s Hospital of Philadelphia.
Kidney disease evaluation
B6.Pdss2kd/kd mice were placed in metabolic cages without food for
24 h with 0.45% NaCl and 2.5% sucrose in the drinking water. Totalwww.embomolmed.org EMBO Mol Med 3, 410–427urine volumes were measured and aliquots of urine were tested for
albumin concentration by enzyme-linked immunosorbent assay
(ELISA). Upon termination of each experiment, mice were euthanized
and their kidneys were fixed and stained with haematoxylin and eosin.
Histologic sections were scored blindly according to the following
scale: 0¼no tubular dilatation and no mononuclear cell infiltrates;
1¼ small focal areas of cellular infiltration and tubular dilatation
involving less than 10% of the cortex; 2¼ involvement of up to 25%
of the cortex; 3¼ involvement of up to 50% of the cortex; and
4¼ extensive damage involving more than 75% of the cortex.
Mechanistic investigations in Pdss2 mouse tissues
Detailed methods of all biochemical and genomic assays reported in
this manuscript are described in Supporting information File 13.Author contributions
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